臨床研究および検査研究の記録

  • ISSN: 2386-5180
  • ジャーナル h-index: 17
  • 雑誌引用スコア: 6.26
  • ジャーナルのインパクトファクター: 5.31
インデックス付き
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • パブロン
  • ユーロパブ
  • Google スカラー
  • シェルパ・ロメオ
  • 秘密検索エンジン研究所
このページをシェアする

抽象的な

Genome-Wide DNA Methylation Profiling Uncovers Competitor Biomarkers and Plausible Atomic System of Metabolic Disorder

Su-jeong park*

Answering the worldwide need to give proof on the effect of interruptions and their moderation, the COVID-19 and Cancer Global Modeling Consortium (CCGMC) was laid out in May 2020. The CCGMC plans to orchestrate pertinent proof on COVID-19 and disease and arrange demonstrating stages that illuminate decision-production in malignant growth control. The CCGMC has created three interrelated work streams, measuring the effect of COVID-19 on malignant growth results, screening and analysis, and disease risk. The accentuation is on creating framework that will permit scattering of persistently refreshed short-and long haul projections of malignant growth significant results. There is a significant spotlight on assessing likely prioritization and recuperation methodologies during and following the serious social and wellbeing administrations interruptions experienced around the world.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません